The Prognostic Value of LncRNA SLNCR1 in Cancers: A Meta-Analysis

Table 1

Characteristics of studies included in the meta-analysis.

Study (year)	Region	Cancer type	Sample size	Age (low/high)	Male (low/high); Female (low/high)	Tumor size (low/high)	LNC00673 high expression			LNC00673 low expression			TNM (low/high)	HR (95% CI)	Cutoff	Method	NOS
							Total	LNM	DM	Total	LNM	DM
Feng (2018) [14]	China	CRC	71	>60 (19/18); ≤60 (16/18)	20/23; 15/13	≤5 cm (23/10); >5 cm (12/26)	36	21	14	35	10	5	—	2.43 (1.02–5.81)	Median	Q-PCR	6
Shi (2016) [15]	China	NSCLC	80	<65 (17/22); ≥65 (22/19)	31/27; 8/14	<5 cm (27/17); ≥5 cm (12/24)	41	23	—	39	13	—	I + II (31/23); III + IV (8/18)	—	NR	Q-PCR	6
Tan (2017) [16]	China	NSCLC	76	>60 (17/19); ≤60 (21/19)	32/25; 6/13	≤3 cm (6/12); >3 cm (32/26)	—	—	—	—	—	—	—	—	Median	Q-PCR	6
Zheng (2019) [17]	China	EOC	131	<50 (18/23); ≥50 (47/43)	—	<1 cm (57/64); ≥1 cm (8/2)	66	44	—	65	23	—	I + II (27/15); III + IV (38/51)	1.66 (0.23–11.91)	Median	Q-PCR	7
Ba (2017) [18]	China	GC	79	≤55 (18/31); >55 (15/15)	17/31; 16/15	<5 cm (23/26); >5 cm (10/20)	46	37	25	33	13	9	I + II (19/10); III + IV (14/36)	1.95 (1.11–3.45)	Median	Q-PCR	6
Huang (2017) [19]	China	GC	73	>65 (18/16); ≤65 (25/14)	23/19; 20/11	≤5 cm (28/11); >5 cm (15/19)	30	24	—	40	24	—	I + II (25/10); III + IV (18/20)	3.81 (1.74–8.32)	FC > 2	Q-PCR	6
Xia (2018) [20]	China	THCA	60	≤45 (15/11); >45 (15/19)	15/9; 15/21	≤10 cm (15/6); >10 cm (15/24)	30	21	1	30	11	3	I + II (20/18); III + IV (10/12)	—	Median	Q-PCR	7
Yu (2016) [21]	China	TSCC	202	≤50 (44/62); >50 (48/48)	76/102; 16/8	T1 (19/11); T2–T4 (73/99)	110	50	0	92	28	0	I + II (58/51); III + IV (34/59)	1.79 (1.00–3.21)	NR	Q-PCR	6
Zhang (2018) [22]	China	PC	229	>60 (51/57); ≤60 (58/63)	—	—	120	59	43	109	47	30	I + II (58/79); III + IV (38/54)	1.91 (1.06–3.46)	NR	Q-PCR	7
Qiao (2019) [23]	China	BC	80	<50 (17/21); ≥50 (23/19)	—	≤2 cm (21/10); >2 cm (19/30)	40	30	—	40	23	—	I + II (39/35); III + IV (1/5)	1.81 (0.44–7.46)	NR	Q-PCR	6
Xia (2018) [24]	China	BC	35	≤60 (10/18); >60 (3/4)	—	≤5 cm (13/20); >5 cm (0/2)	22	15	—	13	4	—	I + II (10/7); III + IV (3/15)	—	Median	Q-PCR	6
Zhou (2020) [25]	China	ESCC	39	>60 (18/11); ≤60 (29/23)	33/27 14/7	≤5 cm (7/12); >5 cm (40/22)	—	—	—	—	—	—	I + II (21/16); III + IV (26/18)	—	Median	Q-PCR	7

CRC, colorectal cancer; NSCLC, nonsmall cell lung cancer; EOC, epithelial ovarian cancer; GC, gastric cancer; THCA, thyroid carcinoma; TSCC, tongue squamous cell carcinoma; PC, pancreatic cancer; BC, breast cancer; LNM, lymph node metastasis; DM, distant metastasis; HR, hazard ratio; NR, not reported; FC, fold change; qRT-PCR, quantitative real-time-polymerase chain reaction; NOS, Newcastle–Ottawa Scale.